Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tafuri

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Frontiers in Oncology|March 4, 2026
Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Frontiers in Oncology|March 27, 2026
Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Nature|May 9, 2001
ICOS is essential for effective T-helper-cell responsesA Tafuri, A Shahinian, F Bladt, et al.
Nature|December 2, 1999
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligandY Y Kong, U Feige, I Sarosi, et al.
Leukemia|October 3, 2002
Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemiaM Mancini, M L Vegna, G L Castoldi, et al.
World Journal of Urology|July 10, 2019
Best practices in near-infrared fluorescence imaging with indocyanine green (NIRF/ICG)-guided robotic urologic surgery: a systematic review-based expert consensusGiovanni E Cacciamani, A Shakir, A Tafuri, et al.
Nature|January 5, 2000
T-cell co-stimulation through B7RP-1 and ICOSS K Yoshinaga, J S Whoriskey, S D Khare, et al.
Frontiers in Pharmacology|April 10, 2023
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life studyA Iurlo, D Cattaneo, D Consonni, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Frontiers in Oncology|March 4, 2026
Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Frontiers in Oncology|March 27, 2026
Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Nature|May 9, 2001
ICOS is essential for effective T-helper-cell responsesA Tafuri, A Shahinian, F Bladt, et al.
Nature|December 2, 1999
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligandY Y Kong, U Feige, I Sarosi, et al.
Leukemia|October 3, 2002
Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemiaM Mancini, M L Vegna, G L Castoldi, et al.
World Journal of Urology|July 10, 2019
Best practices in near-infrared fluorescence imaging with indocyanine green (NIRF/ICG)-guided robotic urologic surgery: a systematic review-based expert consensusGiovanni E Cacciamani, A Shakir, A Tafuri, et al.
Nature|January 5, 2000
T-cell co-stimulation through B7RP-1 and ICOSS K Yoshinaga, J S Whoriskey, S D Khare, et al.
Frontiers in Pharmacology|April 10, 2023
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life studyA Iurlo, D Cattaneo, D Consonni, et al.
Pageof 9